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We have used the technique of short-term infusion with digitonin to obtain hepatocytes originating either from the peri- 
portal or the perivenous zone of the liver acinus [(1985) Biochem. J 229, 221-226]. Total glycogen phosphorylase content 
and sensitivity to cyclic AMP-dependent and calcium-mediated glycogenolytic agonists were very similar for both cell 
sub-populations and did not differ from the values obtained for control cells. We conclude therefore that there is an 
apparent absence of metabolic zonation as far as receptor-mediated glycogenolysis and glycogenolytic potency is 
concerned. 
Glycogenolysis; Metabolic zonation; Hormone; (Hepatocyte) 
1. INTRODUCTION 
The liver performs a variety of key functions in 
the organism where it is not only responsible for 
the maintenance of the energy supply but also 
catalyzes various important biosynthetic and 
biodegradative processes. As reviewed recently by 
Jungermann [2] metabolic zonation of the liver is 
clearly involved in the realization of many of these 
different functions. Histochemically, different 
types of hepatocytes have indeed been detected; 
based on the blood stream, the liver can be con- 
sidered as being composed of at least two func- 
tionally different zones, the periportal and the 
perivenous zones. The periportal cells, for in- 
stance, are better equipped to perform 
gluconeogenesis whereas perivenous hepatocytes 
contain more key enzymes for glycolysis. To our 
knowledge, no data are available concerning the 
glycogenolytic capacity or regulation of the two 
sub-populations of hepatocytes. We have therefore 
undertaken a study to check whether perivenous or 
periportal hepatocytes would present different 
glycogenolytic sensitivities towards well establish- 
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ed glycogenolytic agonists. We have selected 
glucagon as the prototype of cyclic AMP-mediated 
hormones and angiotensin, vasopressin and the 
Crl-adrenergic agonist, phenylephrine, which are 
well known to initiate a calcium-dependent 
glycogenolytic response. ATP was also included 
since this nucleotide exerts a powerful 
glycogenolytic effect [3-6] most probably at the 
level of the PEv-purinoceptors [7]. 
Glutamate dehydrogenase (GDH) activity is 
used as the criterion to decide whether the cell 
preparations are enriched in perivenous or peripor- 
tal cells. Indeed, GDH is found predominantly in 
the perivenous region of the liver acinus, resulting 
in periportal/perivenous ratio equal to 0.72 [8]. 
2. EXPERIMENTAL 
2.1. Materials 
We used male Wistar-strain albino rats (200-250 g body wt) 
that were fed ad libitum. Digitonin was from Serva (Heidelberg, 
FRG) and was rendered water soluble as described by Quistorff 
[1]. Collagenase was from Sigma (St. Louis, MO); other 
chemicals were of the purest grade available. 
2.1.1. Preparation of hepatocytes originating from the 
periportal or the perivenous location in the liver acini 
We have used the combined igitonin/collagenase perfusion 
technique described by Quistorff [l] except hat the infusion of 
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digitonin was done at 20 mg/ml and was stopped after 20 to 
30 s. Periportal cells are obtained when digitonin is infused in 
the retrograde way (via the vena cava) thereby destroying 
preferentially the perivenous region of the liver acini. 
Perivenous cells are obtained after the anterograde (via the por- 
tal vein) infusion of digitonin. Control cells are prepared in the 
same way as perivenous or periportal hepatocytes, except for 
the use of digitonin. The incubation and sampling of the liver 
cells were as described by Keppens and De Wulf [9]. Protein 
concentration was determined by the method of Bradford [10] 
with bovine serum albumin as standard. 
2.2. Enzyme assays 
GDH activity was measured according to Bergmeyer [11]. 
Frozen liver biopsies were homogenised in 3 vols of 1.15% KC1 
and further diluted with water to obtain a final dilution of 1/20. 
Frozen liver cells were thawed shortly before the assay. Both the 
liver homogenate and the cell homogenate were treated for 2 to 
3 rain at room temperature with 0.2% Triton X-100 prior to the 
GDH assay. 
Phosphorylase a assay was done as described by Keppens and 
De Wulf [9]. Total glycogen phosphorylase (a+ b) activity was 
determined according to Stalmans and Hers [12]. 
3. RESULTS AND DISCUSSION 
Control cells and hepatocytes, obtained after the 
selective destruction by digitonin of either the 
perivenous or the periportal regions of the liver 
acini, were analysed for their content of GDH ac- 
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Fig. 1. Dose-dependent activation of phosphorylase by different glycogenolytic agonists in periportal and perivenous hepatocytes. 
Periportal (a) and perivenous (b) hepatocytes were incubated for 1 min with increasing concentrations of glucagon (©), vasopressin 
(e), angiotensin ( A ) and phenylephrine ( [] ) or for 20 s with increasing concentrations of ATP (• ) .  Phosphorylase a was then assayed 
and is expressed as percent increases above control. Values shown are means of 4 to 5 (see table) different experiments. Control and 
maximally stimulated phosphorylase values range from 20-30 to 70-80 mU/mg protein respectively for both perivenous and 
periportal cells. 
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Table 1 
KA values for the glycogenolytic agonists 
Cells Glucagon Vasopressin Angiotensin Phenylephrine ATP 
10 -I° M 10 -I° M 10 -t° M 10 -6 M l0 -6 M 
Control 1.0 +_ 0.4(5) 0.9 ± 0.2(5) 1.2 _+ 0.5(5) 0.97 ± 0.4(4) 1.0 ± 0.5(5) 
Periportal 1.1 ± 0.2(5) 1.1 ± 0.1(5) 2.2 _+ 0.5(5) 0.85 ± 0.2(5) 1.1 _+ 0.2(5) 
Perivenous 1.6 ± 0.4(5) 1.3 _+ 0.2(5) 2.0 ± 0.5(4) 0.76 ± 0.2(4) 1.2 ± 0.3(4) 
These values were computed as indicated in the text and are given as means + SD (n) 
tivity. The ratio of GDH activity of a cell suspen- 
sion over the GDH activity of a biopsy, taken from 
the same liver before digitonin treatment, is used 
for the ascertainment of the zonal origin of the 
ceils. For control cells, due to the elimination of in- 
ert proteins, the GDH activity ratio (_+ SD) 
cell/biopsy was 1.45 _+ 0.11(5); for the presumed 
perivenous and periportal cells, this ratio was 1.68 
_+ 0.3(6) and 1.05 + 0.24(5), respectively (P < 0.05 
by the Student's t-test). This gives a peripor- 
tal/perivenous activity ratio of 0.62, a clear indica- 
tion (see section 1) for a selective nrichment in 
periportal and perivenous hepatocytes. 
Cell populations enriched in either perivenous or 
periportal hepatocytes were preincubated with 
10 mM glucose to lower their phosphorylase a con- 
tent to 20-30 mU/mg of protein in both instances 
(see legend to fig. 1). They were then challenged for 
1 min with increasing concentrations of a 
glycogenolytic agonist, except for ATP where the 
exposure of the cells was reduced to 20 s. We have 
shown previously [3,9] that both time intervals are 
largely sufficient to allow the development of en- 
zyme activation. As is shown in fig. 1, each agonist 
produced a quite similar dose-dependent ac ivation 
of glycogen phosphorylase in the periportal and 
perivenous cell preparations. In both cell popula- 
tions maximal activations are similar albeit 
somewhat lower with phenylephrine and ATP. KA 
values (agonist concentrations at which half max- 
imal activation isobtained) have been computed as 
described previously [3,13-15]; they are tabulated 
in table 1, and are compared with control values. 
No statistically significant differences (as obtained 
by the Student's t-test) are revealed between the KA 
values obtained with periportal or perivenous 
hepatocytes for a given agonist. Due to the in- 
herent variability, small changes (up to 2-fold) in 
KA values might be overlooked. We conclude 
therefore that perivenous and periportal 
hepatocytes cannot be distinguished from each 
other with respect to their receptor-mediated 
glycogenolysis, whether this process is mediated by 
cyclic AMP (glucagon) or by calcium ions 
(phenylephrine, vasopressin, angiotensin and 
ATP). Total (a+ b) activity (mU/mg protein +_ 
SD) of glycogen phosphorylase was 96.6 _+ 15.0(5) 
for periportal cells and 90.3 _+ 10.8(5) for 
perivenous cells, indicating that both cell types 
possess the same glycogenolytic potency. 
These data do not however exclude an in vivo 
occurrence of zonation of hormonal glycogenoly- 
sis. Indeed, using a perfused system, H~iussinger 
et al. [16] reported on liver heterogeneity in
response to extracellular ATP, the periportal area 
being more responsive to ATP than the perivenous 
hepatocytes. These data are not necessarily in con- 
tradiction with our findings showing no different 
glycogenolytic capacity between hepatocytes 
originating from the two zones. Factors existing in 
vivo and lost in vitro upon isolation of the 
hepatocytes, might result in some in situ metabolic 
zonation. The existence in vivo of hormone, 
substrate and product gradients [2], the possible 
influence of hemodynamic changes induced by the 
agonists tested in vivo are a few examples of dif- 
ferences between in vivo and in vitro conditions. 
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